Françoise Picarel-Blanchot Selected Research

agomelatine (S20098)

1/2021	Efficacy of Agomelatine 25-50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies.
1/2021	The safety of agomelatine in standard medical practice in depressed patients: A 26-week international multicentre cohort study.
10/2018	Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder.
1/2018	12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.
1/2018	Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder.
1/2017	Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.
2/2016	Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months.
2/2010	Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Françoise Picarel-Blanchot Research Topics

Disease

5	Major Depressive Disorder (Major Depressive Disorders) 01/2021 - 02/2010
3	Anxiety Disorders (Anxiety Disorder) 01/2021 - 01/2017
1	Stroke (Strokes) 02/2020
1	Ischemic Stroke 02/2020
1	Insulin Resistance 01/2008
1	Prediabetic State (Prediabetes) 01/2008

Drug/Important Bio-Agent (IBA)

8	agomelatine (S20098)IBA 01/2021 - 02/2010
1	S44819IBA 02/2020
1	Escitalopram FDA Link 01/2018
1	VortioxetineIBA 01/2018
1	Antidepressive Agents (Antidepressants)IBA 02/2010
1	Sertraline (Zoloft)FDA LinkGeneric 02/2010
1	Glucose (Dextrose)FDA LinkGeneric 01/2008
1	Insulin (Novolin)FDA Link 01/2008

Therapy/Procedure

1	Activities of Daily Living (ADL) 02/2020